2021-05-20 08:00
May 20, 2021 - Biovica, active in cancer diagnostics, today announces that DiviTumTKa shows prognostic and predictive capabilities in metastatic cutaneous melanoma patients undergoing immunotherapy. These results from a new study at Karolinska University...
2021-04-29 11:00
Biovica, active in cancer diagnostics, today announced that the company has strengthened the management team with Helle Fisker as new commercial manager and Joakim Arwidson as new quality and regulatory manager. Helle Fisker has more than 25 years of...
2021-04-23 08:30
Biovica, active in cancer diagnostics, today announced that the results from a budget impact model of monitoring with DiviTum®TKa can give savings of up to three times the extra spend relative to current management. The results will be presented at...
2021-03-18 08:00
FDA resumes review of DiviTum®TKa submission Significant events during the third quarter Significant events after the end of the period Audiocast: When: 18 March 2021 at 10.00 CET Where: https://tv.streamfabriken.com/biovica-international-q3-2020-2021...
2021-03-11 11:10
Biovica, active in cancer diagnostics, today announced that the results from the breast cancer study PROMIX at Karolinska University Hospital is published in the scientific journal ESMO Open. The study showed that testing for TKa levels during early treatment...
2021-02-26 08:00
The Nomination Committee prior to the 2021 Annual General Meeting will consist of three members, who shall represent the two shareholders with the most number of shares who accept the assignment to be part of the Nomination Committee as of December 31...
2021-01-29 20:20
Biovica, active in cancer diagnostics, today announced that the US Food and Drug Administration (FDA) has resumed its review of Biovica’s 510(k)-submission for DiviTum®TKa. “This is fantastic news on our journey to make the test available...
2021-01-18 08:00
DiviTum®TKa has been selected to be included in the new prospective clinical study TIRESIAS, with the aim of investigating if DiviTum®TKa can be used to identify early resistance to treatment by a CDK4/6 inhibitor in combination with an aromatase...
2021-01-16 12:48
Biovica, active in cancer diagnostics, today announced that the US Food and Drug Administration (FDA) has indicated that its previously communicated reallocation of resources to address COVID-19 continues to impact the timeline for completion of the review...
2021-01-12 11:50
Biovica's CEO and main shareholder Anders Rylander has, to facilitate the administration of the company's warrant program 3, lent 127,000 shares to Pareto Securities AB. The program comprises 200,000 options, of which 145,000 options have been...
>4,500
Numbers of patients in studies
28
Publications
22
Pharma Projects